Aragon Pharmaceuticals has announced the dosing of the first patient in its Phase I study of ARN-810 in estrogen receptor-positive breast cancer.
The Phase I dose escalation study, which will be conducted at Vanderbilt University, Mass General Hospital and Memorial Sloan-Kettering Cancer Center, will assess the safety and tolerability of ARN-810.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
ARN-810 is an oral selective estrogen receptor degrader (SERD) designed to treat locally advanced or metastatic estrogen receptor-positive breast cancer in post-menopausal women.
The nonsteroidal agent degrades the receptor by binding to the estrogen receptor, inducing a conformational change.
Aragon Pharmaceuticals CEO Richard Heyman said ARN-810 is the most advanced candidate in its novel SERD programme.
"Today’s announcement represents a landmark step for us, as our SERD program originated within Aragon and is wholly-owned," Heyman said.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"We are hopeful that ARN-810’s novel approach to breast cancer therapy will prove to be a more effective, sustained treatment option for this important patient population."
The Vanderbilt-Ingram Cancer Center clinical research associate director and breast cancer programme director Dr Carlos Arteaga said; "This drug may become another treatment option for many women with breast cancer."
